Provided by Tiger Trade Technology Pte. Ltd.

Aclaris Therapeutics

5.99
-0.0650-1.07%
Volume:722.76K
Turnover:4.36M
Market Cap:880.99M
PE:-10.21
High:6.24
Open:6.09
Low:5.95
Close:6.05
52wk High:6.60
52wk Low:1.74
Shares:147.20M
Float Shares:110.00M
Volume Ratio:0.78
T/O Rate:0.66%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5861
EPS(LYR):-0.5300
ROE:-59.10%
ROA:-28.98%
PB:7.07
PE(LYR):-11.29

Loading ...

Oppenheimer Initiates Aclaris Therapeutics at Outperform With $10 Price Target

MT Newswires Live
·
Apr 16

Aclaris Therapeutics Inc : Oppenheimer Initiates Coverage With Outperform Rating; Price Target $10

THOMSON REUTERS
·
Apr 16

Aclaris Therapeutics Initiated at Outperform by Oppenheimer

Dow Jones
·
Apr 16

U.S. RESEARCH ROUNDUP-CME Group, M&T Bank, PNC Financial Services

Reuters
·
Apr 16

Cardiff Oncology names Mani Mohindru CEO, appoints Josh Muntner CFO

Reuters
·
Apr 10

Aclaris CEO to join fireside chat at H.C. Wainwright skin disease conference

Reuters
·
Apr 08

Aclaris Therapeutics Price Target Maintained With a $8.00/Share by Wedbush

Dow Jones
·
Mar 31

Aclaris Therapeutics Phase 2a week 12 EASI improvement climbs 77% on ATI-2138 10 mg BID; BSA improvement grows 70%

Reuters
·
Mar 27

Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138

GlobeNewswire
·
Mar 27

Aclaris Therapeutics to present Phase 2a ATI-2138 atopic dermatitis trial results at 2026 AAD meeting

Reuters
·
Mar 20

Aclaris Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 19

Aclaris Therapeutics completes enrollment of 109 patients in Phase 2 bosakitug trial for atopic dermatitis

Reuters
·
Mar 18

Aclaris Therapeutics Inc - Top Line Results From Phase 2 Trial Expected in Q4 2026

THOMSON REUTERS
·
Mar 18

Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

GlobeNewswire
·
Mar 18

Aclaris Therapeutics Raises $20 Million in Equity Financing

TIPRANKS
·
Mar 12

Aclaris Therapeutics sells 5.7 million shares for USD 20 million

Reuters
·
Mar 12